Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, USA.
Cleve Clin J Med. 2012 Jan;79(1):38-43. doi: 10.3949/ccjm.79a.11166.
The AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) found, in an interim analysis, no cardiovascular benefit from taking extended-release niacin (Niaspan). In fact, there was a trend toward a greater risk of ischemic stroke, which did not reach statistical significance. But questions remain about this complex trial, which included intensive statin therapy in the active-treatment group and the control group.
AIM-HIGH 试验（代谢综合征伴低 HDL/高甘油三酯人群中的动脉粥样硬化血栓形成干预：对全球健康结局的影响）进行中期分析时发现，服用烟酸缓释剂（Niaspan）并不能带来心血管获益。事实上，缺血性卒中的风险呈增加趋势，但未达到统计学显著性。但是，对于这个包含强化他汀治疗的试验，仍存在一些疑问，该试验包括活性治疗组和对照组。
